ICYMI, this week we had stories about what to look forward to in 2023, psoriasis challenges, NDA submissions for berdazimer gel, and more.
The Dermatology Times® Editorial Advisory Board members share what they hope to see in 2023.
More drugs and treatment options continue to be explored, and in 2022, there were some exciting advancements in these areas for dermatologists treating psoriasis.
This week's edition of the Mainstream Patient features stories about dry shampoos that don't contain benzene, the best ferulic acid serums, Hijabi hair care, and more.
Patients with psoriasis seem to suffer more in the wintertime when flare-ups are much more common.
Although Merkel cell carcinoma can develop undetected or at a metastasized site, it usually first appears as a painless lump or nodule on an area of the skin that has been exposed to the sun.
In basal cell carcinoma, the most common type of skin cancer accounting for 80% of all non-melanoma skin cancers, one of the leading options for cases that fall into this category is targeted treatment with Hedgehog pathway inhibitors.
Answers to some common questions about providing telehealth services in 2023.
New clues about the immune system response to MCC may be able to help guide future treatment strategies.
In this week’s Pointers with Dr Portela, the 208SkinDoc discusses if telehealth is here to stay in dermatology.
New pathways of care are needed to improve health care spending.
New products focus on multimodal healing with absorption, antibacterial, and regenerative properties.
This month's Legal Eagle column reviews how a patient tried to sue for battery due to excess swelling after dermal fillers.
Potential FDA approval is expected in the first quarter of 2024.
VP-102 could be the first approved drug on the market in the US to treat molluscum contagiosum.